[18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases
Authors:
- 15 October 2024
- journal article
- research article
- Published by Elsevier in European Journal of Radiology
- Vol. 181, 111791
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PETAnnals of Oncology, 2024
- Imaging in metastatic breast cancer, CT, PET/CT, MRI, WB-DWI, CCA: review and new perspectivesCancer Imaging, 2023
- 18F-Fluoroestradiol: Current Applications and Future DirectionsRadioGraphics, 2023
- [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with RintodestrantClinical Cancer Research, 2023
- Breast Cancer Patients with Brain Metastases: A Cross-Sectional StudyThe Breast Journal, 2022
- Breast cancer: initial workup and staging with FDG PET/CTClinical and Translational Imaging, 2021
- Treatment strategies for breast cancer brain metastasesBritish Journal of Cancer, 2020
- PET imaging in patients with brain metastasis—report of the RANO/PET groupNeuro-Oncology, 2019
- Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast CancerClinical Cancer Research, 2011
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004